Antiemetics: Technologies and Global Markets
Report Scope
The report details the antiemetic drug market. The analysis highlights current and future market potential for antiemetic drug and presents a detailed review of pipeline drugs, blockbuster drugs, and challenges to market growth. The report also examines disease burden, regulatory environment, novel technologies, and market projections to 2023. Antiemetic drug market drivers, trends and potential regional market opportunities are also covered in this report.
The report details market shares of antiemetic drug class (5-HT3 receptor antagonists, dopamine antagonists, steroid-corticosteroids, benzodiazepines, NK1 receptor antagonist, antihistamines, cannabinoids, and anticholinergic) and geographic market segmentation of overall market; global market share by applications, with special emphasis on developed and underdeveloped geographic regions. For market estimates, data has been provided for 2017, as base year, 2018 and forecast for 2023.
Report Includes
- 21 data tables and 15 additional tables
- Country specific data and analysis for United States, Canada, Mexico, France, Germany, UK, China, India, Japan, and Middle East and Africa
- An overview about current and future market potential for antiemetic drugs with special focus on competitive environment, pipeline drugs and blockbuster drugs
- Coverage of disease burden, regulatory environment, and novel technologies in the antiemetic drugs market
- Detailed description about vestibular disorder and increasing demand of innovative technology for treatment
- Exploration of the causes of emesis, usage of antiemetics and the types of products available to treat nausea and vomiting by each application segment
- Information about the launching of new drugs in each antiemetic drug class such as 5 HT3 receptor antagonists, dopamine antagonists, NK1 receptor antagonist, and so forth
- Detailed company profiles of major players in the market, including Abbott Laboratories, Daiichi Sankyo Company, Ltd., Merck & Co., Novartis AG, Sanofi Aventis and Teva Pharmaceutical Industries Ltd.
- Chapter 1 Introduction
- Antiemetic Technologies
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Related BCC Research Reports
- Chapter 2 Summary and Highlights
- Chapter 3 Overview
- Introduction
- Causes of Nausea and Vomiting
- Gastrointestinal Obstruction/Infection/Inflammation
- Drug-Induced Nausea and Vomiting
- Pregnancy-Induced Nausea and Vomiting
- Post-operative Nausea and Vomiting
- Vestibular Disorder
- Pathophysiology of Nausea and Vomiting
- Gastrointestinal Tract
- Chemoreceptor Trigger Zone
- Vestibular Apparatus
- Cerebral Cortex
- Chapter 4 Market and Technology Background
- Drivers
- Global Increase in Number of Pregnancies and Burden of Underlying Disease Conditions
- Increasing in Research Grants and Funding
- Growing Research Activity in Innovative Antiemetic Drug Therapy
- Use of Novel Drug Deliveries to Treat Nausea and Vomiting
- Restraints
- Lack of Animal Models to Prove Efficacy of Antiemetics
- Pricing Pressure Experienced by Innovators
- Availability of Alternative Treatments
- Opportunities
- Disease Burden and Increasing Number of Pregnancies in Europe and Asia-Pacific
- Vestibular Disorders
- Emergence of Advanced Therapies
- Patent Expiry
- Chapter 5 Market Breakdown by Drug Class
- Introduction
- Global Antiemetic Drugs Market
- 5-HT3 Receptor Antagonists
- NK1 Receptor Antagonist
- Dopamine Antagonists
- Antihistamines (H1 Receptor Antagonists)
- Cannabinoids
- Benzodiazepines
- Corticosteroids
- Anticholinergics
- Chapter 6 Market Breakdown by Application
- Overview
- Market Size and Forecast
- Chemotherapy-Induced Nausea and Vomiting
- Introduction
- Market Size and Forecast
- Key CINV Market Takeaways
- Gastroenteritis
- Market Size and Forecast
- Nausea and Vomiting of Pregnancy (NVP)
- Market Size and Forecast
- Post-Operative Nausea and Vomiting
- Market Size and Forecast
- Chapter 7 Market Breakdown by Region
- Overview
- Market Size and Forecast
- North America
- Market Size and Forecast
- United States
- Canada
- Mexico
- Europe
- Market Size and Forecast
- United Kingdom
- Germany
- Asia-Pacific
- Market Size and Forecast
- Middle East and Africa
- South America
- Chapter 8 Patent Review/New Developments
- Introduction
- Chapter 9 Pipeline Analysis
- Introduction
- NK1 Receptor Antagonists
- Chapter 10 Regulatory Landscape
- Introduction
- Regional Regulatory Landscape
- North America
- Europe
- Asia-Pacific
- Chapter 11 Company Profiles
- ABBOTT LABORATORIES
- Overview
- Financial Information
- Products and Services
- Development and Strategies
- ASTELLAS PHARMA INC.
- Overview
- Financial Information
- Products and Services
- Development and Strategies
- APHIOS CORP.
- Overview
- AUROBINDO PHARMA
- Overview
- Financial Information
- Products and Services
- DAIICHI SANKYO COMPANY LTD.
- Overview
- Financial Information
- Product and Services
- Development and Strategies
- EISAI CO., INC.
- Overview
- Financial Information
- Products and Services
- GLAXOSMITHKLINE PLC
- Overview
- Financial Information
- Products and Services
- HELSINN HEALTHCARE SA
- Overview
- Products and Services
- Key Developments and Strategies
- HERON THERAPEUTICS, INC.
- Overview
- Financials
- Products and Services
- IPCA LABORATORIES, LTD.
- Overview
- KYOWA HAKKO KIRIN PHARMA, INC.
- Overview
- Financials
- MERCK & CO., INC.
- Overview
- Financial Information
- Products and Services
- NOVARTIS AG
- Overview
- Financial Information
- F. HOFFMANN-LA ROCHE AG
- Overview
- Financial Information
- Products and Services
- SANOFI AVENTIS
- Overview
- Financial Information
- Products and Services
- TESARO, INC.
- Overview
- Financial Information
- Products and Services
- Development and strategies
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- Overview
- Financial Information
- Product and Services
- Development and Strategies
- Chapter 12 Appendix: Abbreviations
- List of Tables
- Summary Table A : Global Antiemetic Drugs Market, by Drug Class, Through 2023
- Summary Table B : Global Antiemetic Drugs Market, by Application, Through 2023
- Table 1 : Emetic Potency of Chemotherapeutic Agents
- Table 2 : Vomiting as Adverse Effect at Therapeutic Dosage
- Table 3 : Ondansetron Patent Expiration
- Table 4 : Aloxi Patent Expiration
- Table 5 : List of FDA approved Antiemetic Drugs and Indications
- Table 6 : Global Antiemetic Drugs Market, by Drug Class, Through 2023
- Table 7 : 5-HT3 Receptor Drugs
- Table 8 : FDA Approved Dopamine Antagonists
- Table 9 : Global Antiemetic Drugs Market, by Application, Through 2023
- Table 10 : Global Antiemetic Drugs Market, by Region, Through 2023
- Table 11 : Antiemetic Drug Patents
- Table 12 : Antiemetic Drug Candidates
- Table 13 : FDA Approved Drugs
- Table 14 : List of Antiemetic Drugs Approved in Japan
- Table 15 : Abbott Laboratories: Net Revenue, 2015-2017
- Table 16 : Abbott Laboratories: Net Revenue, by Segment, 2017
- Table 17 : Abbott Laboratories: Marketed Products, 2016
- Table 18 : Astellas Pharma Inc.: Net Revenue, 2015-2017
- Table 19 : Astellas Pharma Inc.: Marketed Products, 2016
- Table 20 : Aurobindo Pharma Ltd.: Net Revenue, 2015-2017
- Table 21 : Daiichi Sankyo Company Ltd.: Net Revenue, 2015-2017
- Table 22 : Eisai Co., Inc.: Net Revenue, by Region, 2014-2016
- Table 23 : Eisai Co., Inc.: Oncology Product Sales, 2014-2016
- Table 24 : GlaxoSmithKline PLC: Net Revenue, 2014-2016
- Table 25 : Heron Therapeutics Inc.: Net Revenue, 2016-2017
- Table 26 : Kyowa Hakko Kirin Pharma Inc.: Net Revenue, 2013-2017
- Table 27 : Merck & Co. Inc.: Net Revenue, 2014-2016
- Table 28 : Novartis AG: Net Revenue, 2014-2016
- Table 29 : F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, Through 2017
- Table 30 : Sanofi: Net Revenue, 2014-2016
- Table 31 : Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2017
- Table 32 : Teva Pharmaceutical Industries Ltd.: Net Revenue, by Segments, 2015-2017
- Table 33 : Teva Pharmaceutical Industries Ltd: Products and Services
- Table 34 : Abbreviations
- List of Figures
- Summary Figure A : Global Antiemetic Drugs Market, by Drug Class, 2017-2023
- Summary Figure B : Global Antiemetic Drugs Market, by Application, 2017-2023
- Figure 1 : Mechanism of Chemotherapy-Induced Nausea and Vomiting
- Figure 2 : Pathophysiology of Nausea and Vomiting
- Figure 3 : Pathophysiology of Emesis
- Figure 4 : Global Antiemetic Drugs Market, by Drug Class, 2017-2023
- Figure 5 : Global Market Share of Antiemetics, by Drug Class, 2017
- Figure 6 : Global 5-HT3 Receptor Market, 2017-2023
- Figure 7 : Global NK1 Receptor Antagonist Market, 2017-2023
- Figure 8 : Global Dopamine Receptor Market, 2017-2023
- Figure 9 : Global Antihistamines Receptor Antagonist Market, 2017-2023
- Figure 10 : Global Cannabinoids Market, 2017-2023
- Figure 11 : Global Benzodiazepines Market, 2017-2023
- Figure 12 : Global Corticosteroid Market, 2017-2023
- Figure 13 : Global Anticholinergic Drugs Market, 2017-2023
- Figure 14 : Global Market Share for Antiemetics Drug, by Application, 2017
- Figure 15 : Global CINV Drugs Market, 2017-2023
- Figure 16 : Global Gastroenteritis Antiemetic Drug Market, 2017-2023
- Figure 17 : Global NVP Antiemetic Drug Market, 2017-2023
- Figure 18 : Global PONV Antiemetic Drugs Market, 2017-2023
- Figure 19 : Global Antiemetic Drugs Market, by Region, 2017-2023
- Figure 20 : North America Antiemetic Drugs Market, 2017-2023
- Figure 21 : North America Antiemetic Drugs Market, by Application, 2017-2023
- Figure 22 : Europe Antiemetic Drugs Market, 2017-2023
- Figure 23 : Europe Antiemetic Drugs Market, by Application, 2017-2023
- Figure 24 : Asia-Pacific Antiemetic Drugs Market, 2017-2023
- Figure 25 : Asia-Pacific Antiemetic Drugs Market, by Application, 2017-2023
- Figure 26 : Middle East and Africa Antiemetic Drugs Market, 2017-2023
- Figure 27 : South America Antiemetic Drugs Market, 2017-2023
- Figure 28 : Abbott Laboratories: Revenue Share, by Segment, 2017
- Figure 29 : Astellas Pharma Inc.: Revenue Share, by Segment, 2017
- Figure 30 : Aurobindo Pharma Ltd.: Revenue Share, by Segment, 2017
- Figure 31 : Daiichi Sankyo Company Ltd.: Revenue Share, by Business Segment, 2016
- Figure 32 : GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2016
- Figure 33 : GlaxoSmithKline PLC: Revenue Share, by Region, 2016
- Figure 34 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2016
- Figure 35 : Merck & Co. Inc.: Revenue Share, by Region, 2016
- Figure 36 : Novartis AG: Revenue Share, by Region, 2016
- Figure 37 : Novartis AG: Revenue Share, by Business Segment, 2016
- Figure 38 : F. Hoffmann-La Roche Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016
- Figure 39 : Sanofi: Revenue Share, by Region, 2016
- Figure 40 : Sanofi: Revenue Share, by Business Segment, 2016
- Figure 41 : Sanofi: Revenue Share, by Pharmaceuticals Segment, 2017
- Figure 42 : Tesaro, Inc.: Net Revenue, 2015-2017
- Figure 43 : Teva Pharmaceutical Industries Ltd.: Generic Medicines Segment Revenue Share, by Region, 2017